Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study

BACKGROUND: Rotavirus vaccines reduce rotavirus-related deaths and hospitalisations but are less effective in high child mortality countries. The human RV3-BB neonatal G3P[6] rotavirus vaccine administered in a neonatal schedule was efficacious in reducing severe rotavirus gastroenteritis in Indones...

Descripción completa

Detalles Bibliográficos
Autores principales: Witte, Desiree, Handley, Amanda, Jere, Khuzwayo C, Bogandovic-Sakran, Nada, Mpakiza, Ashley, Turner, Ann, Pavlic, Daniel, Boniface, Karen, Mandolo, Jonathan, Ong, Darren Suryawijaya, Bonnici, Rhian, Justice, Frances, Bar-Zeev, Naor, Iturriza-Gomara, Miren, Ackland, Jim, Donato, Celeste M, Cowley, Daniel, Barnes, Graeme, Cunliffe, Nigel A, Bines, Julie E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021029/
https://www.ncbi.nlm.nih.gov/pubmed/35065683
http://dx.doi.org/10.1016/S1473-3099(21)00473-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021029/
https://www.ncbi.nlm.nih.gov/pubmed/35065683
http://dx.doi.org/10.1016/S1473-3099(21)00473-4

Ejemplares similares